Nicotine patch litigation
Ciba-Geigy's request for a preliminary injunction against Marion Merrell Dow/Alza's Nicoderm smoking cessation patch is denied in federal court in Newark, N.J. on Dec. 20. Ciba-Geigy said it plans to pursue further legal action against Alza and MMD. In the meantime, Nicoderm's launch will proceed. In a separate case, Elan and U.S. marketing partner Lederle withdrew motion for a preliminary injunction against Ciba-Geigy's Habitrol patch on Dec. 18. The companies said that "the urgency for relief on the basis of irreparable damages no longer had an adequate legal foundation" after the Dec. 13 lifting of a temporary restraining order that had prevented the marketing of Nicoderm. Elan/Lederle had obtained the restraining order Nov. 21 pending a ruling on their request for a preliminary injunction ("The Pink Sheet" Dec. 16, T&G-3).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth